Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092114769> ?p ?o ?g. }
- W3092114769 abstract "IgA nephropathy (IgAN) is the commonest biopsy-reported primary glomerulonephritis worldwide. It has an incidence which peaks among young adults, and 30 to 40% of patients' progress to end stage kidney disease within twenty years of diagnosis. Ten-year kidney survival rates have been reported to be as low as 35% in some parts of the world. The successful management of IgAN is limited by an incomplete understanding of the pathophysiology of IgAN and a poor understanding of how pathophysiology may vary both from patient to patient and between patient groups, particularly across races. This is compounded by a lack of rigorously designed and delivered clinical trials in IgAN. This is slowly changing, with a number of Phase 2 and 3 clinical trials of novel therapies targeting a number of different putative pathogenic pathways in IgAN due to report in the next 5 years. From our current, albeit limited, understanding of the pathophysiology of IgAN it is unlikely a single therapy will be effective in all patients with IgAN. The successful management of IgAN in the future is, therefore, likely to be reliant on targeted therapies, carefully selected based on an individualized understanding of a patient's risk of progression and underlying pathophysiology. The potential role of biomarkers to facilitate personalization of prognostication and treatment of IgAN is immense. Here we review the progress made over the past decade in identifying and validating new biomarkers, with a particular focus on those that reflect immunological responses in IgAN." @default.
- W3092114769 created "2020-10-15" @default.
- W3092114769 creator A5025808184 @default.
- W3092114769 creator A5026871566 @default.
- W3092114769 creator A5044604694 @default.
- W3092114769 creator A5055078486 @default.
- W3092114769 creator A5060496810 @default.
- W3092114769 date "2020-10-06" @default.
- W3092114769 modified "2023-10-10" @default.
- W3092114769 title "Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management" @default.
- W3092114769 cites W1521092514 @default.
- W3092114769 cites W1525836415 @default.
- W3092114769 cites W1530872697 @default.
- W3092114769 cites W1604471223 @default.
- W3092114769 cites W1768246186 @default.
- W3092114769 cites W1906440464 @default.
- W3092114769 cites W1907333992 @default.
- W3092114769 cites W1908569206 @default.
- W3092114769 cites W1922859388 @default.
- W3092114769 cites W1963785353 @default.
- W3092114769 cites W1967907448 @default.
- W3092114769 cites W1972076005 @default.
- W3092114769 cites W1973214597 @default.
- W3092114769 cites W1974000182 @default.
- W3092114769 cites W1974689656 @default.
- W3092114769 cites W1975373650 @default.
- W3092114769 cites W1977914294 @default.
- W3092114769 cites W1979078959 @default.
- W3092114769 cites W1979646197 @default.
- W3092114769 cites W1980277295 @default.
- W3092114769 cites W1982085852 @default.
- W3092114769 cites W1982146516 @default.
- W3092114769 cites W1985244471 @default.
- W3092114769 cites W1985647938 @default.
- W3092114769 cites W1987083564 @default.
- W3092114769 cites W1989273660 @default.
- W3092114769 cites W1993704604 @default.
- W3092114769 cites W1994763032 @default.
- W3092114769 cites W2001260124 @default.
- W3092114769 cites W2001327603 @default.
- W3092114769 cites W2002913308 @default.
- W3092114769 cites W2007405428 @default.
- W3092114769 cites W2009486805 @default.
- W3092114769 cites W2010005880 @default.
- W3092114769 cites W2010256345 @default.
- W3092114769 cites W2011358717 @default.
- W3092114769 cites W2012058689 @default.
- W3092114769 cites W2013569247 @default.
- W3092114769 cites W2014711903 @default.
- W3092114769 cites W2014987392 @default.
- W3092114769 cites W2019194362 @default.
- W3092114769 cites W2023745083 @default.
- W3092114769 cites W2023846712 @default.
- W3092114769 cites W2031235799 @default.
- W3092114769 cites W2031971923 @default.
- W3092114769 cites W2032917842 @default.
- W3092114769 cites W2036651304 @default.
- W3092114769 cites W2037461279 @default.
- W3092114769 cites W2040706558 @default.
- W3092114769 cites W2041677815 @default.
- W3092114769 cites W2042060588 @default.
- W3092114769 cites W2042485248 @default.
- W3092114769 cites W2054598438 @default.
- W3092114769 cites W2057402675 @default.
- W3092114769 cites W2058154849 @default.
- W3092114769 cites W2061897900 @default.
- W3092114769 cites W2063340779 @default.
- W3092114769 cites W2063788672 @default.
- W3092114769 cites W2070569398 @default.
- W3092114769 cites W2071615161 @default.
- W3092114769 cites W2073591401 @default.
- W3092114769 cites W2074353891 @default.
- W3092114769 cites W2074850565 @default.
- W3092114769 cites W2075702215 @default.
- W3092114769 cites W2076094379 @default.
- W3092114769 cites W2078871904 @default.
- W3092114769 cites W2079286579 @default.
- W3092114769 cites W2080514914 @default.
- W3092114769 cites W2086627106 @default.
- W3092114769 cites W2090353442 @default.
- W3092114769 cites W2092643558 @default.
- W3092114769 cites W2095142424 @default.
- W3092114769 cites W2096530603 @default.
- W3092114769 cites W2096977413 @default.
- W3092114769 cites W2099088033 @default.
- W3092114769 cites W2101794801 @default.
- W3092114769 cites W2105072395 @default.
- W3092114769 cites W2105595841 @default.
- W3092114769 cites W2107586219 @default.
- W3092114769 cites W2108789237 @default.
- W3092114769 cites W2109037500 @default.
- W3092114769 cites W2111238151 @default.
- W3092114769 cites W2118535365 @default.
- W3092114769 cites W2119503614 @default.
- W3092114769 cites W2120190829 @default.
- W3092114769 cites W2120270278 @default.
- W3092114769 cites W2120300576 @default.
- W3092114769 cites W2120366573 @default.
- W3092114769 cites W2120547009 @default.
- W3092114769 cites W2121260651 @default.